SCHEMBL4579159

SCHEMBL4579159

O=C1CCc2cc(NCC(=O)N3CCC(Oc4ccc(Cl)cc4)CC3)ccc2N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 2/20 0.47
GRIN3B O60391 2/20 0.47
GRIN1 Q05586 2/20 0.47
GRIN2A Q12879 2/20 0.47
GRIN2B Q13224 2/20 0.47
GRIN2C Q14957 2/20 0.47
GRIN3A Q8TCU5 2/20 0.47
IDH1 O75874 1/20 0.46
EPHX2 P34913 3/20 0.44
KCNH2 Q12809 1/20 0.43
PKM P14618 1/20 0.43
BCL6 P41182 1/20 0.42
BCOR Q6W2J9 1/20 0.42
CRBN Q96SW2 2/20 0.41
P2RX3 P56373 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BRD4 O60885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4577645 0.84 IDH1 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15586418 0.83 KCNH2 (0.47) EPHX2KCNH2CRBNUSP2LMNA
SCHEMBL12232292 0.83 KCNH2 (0.52) IDH1KCNH2PKMUSP2LMNA
SCHEMBL4577792 0.80 GRIN2D (0.72) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12233852 0.78 ADAMTS5 (0.49) IDH1PKMP2RX3USP2LMNA
SCHEMBL4578119 0.77 EPHX2 (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4576753 0.77 GRIN2D (0.74) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4577718 0.77 GRIN1 (0.67) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4577391 0.76 OGT (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15533404 0.76 PKM (0.48) KCNH2PKMLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7435744-B2 Piperidine derivatives as NMDA receptor antagonists GEDEON RICHTER VEGYESZETI GYAR RT (HU) 2008-10-14 US disclosed
EP-1409477-B1 PIPERIDINE DERIVATIVES AS NMDA RECEPTOR ANTAGONISTS RICHTER GEDEON NYRT (HU) 2008-09-17 EP disclosed
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists UCB Biopharma SRL (BE) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157886-A1 Piperdine derivatives as NMDA receptor antagonists GRIN1, GRIN2D, GRIN2C GRIN2D 2/4885GRIN3B 9/4885GRIN1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.